ELMSFORD, N.Y., May 09, 2018 (GLOBE NEWSWIRE) — NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it has partnered with Fabrication Enterprises, Inc. to market and distribute NanoVibronix’s PainShield® in the U.S., with a focus on the sports medicine, sports trainer, and physical therapy markets.
Fabrication Enterprises is a leading manufacturer, importer, and master distributor of products for physical therapy, occupational therapy, chiropractic clinics, athletic training, homecare, and more. Founded in 1974, its products are sold to hospitals, clinics, fitness centers, and professionals through a global network of dealers.
In addition, both NanoVibronix and Fabrication Enterprises will feature the product at their respective booths at the NATA 69th Clinical Symposia & AT Expo, which is being held June 26-29 in New Orleans. NATA 2018 is hosted by the National Athletic Trainers’ Association (NATA) and is one of the premier industry conferences targeting the athletic training profession.
Elliott Goldberg, President of Fabrication Enterprises, Inc., stated, “Trainers have a very personal relationship with their clients that often provides them intimate knowledge of their clients’ unique conditions. PainShield has been clinically proven to treat certain types of pain and induce soft tissue healing in targeted areas, which is particularly well-suited for the sports medicine and sports trainer markets. Given the fact it is portable, lightweight, and does not require administration by medical personnel, PainShield can therefore be used by the trainers’ clients without being located in a health care facility or clinic. The advantages of the product are further highlighted by the growing support from a number of professional athletes who have witnessed the benefits of PainShield firsthand and have publicly endorsed the product. We look forward to featuring PainShield at the upcoming NATA 69th Clinical Symposia & AT Expo.”
Brian Murphy, CEO of NanoVibronix, commented, “We are excited to partner with Fabrication Enterprises, a leading distributor of medical devices in the U.S. with over 18 sales representatives and a network of global distributors. This partnership further illustrates the growing interest in PainShield within the personal training sports medicine market. According to the U.S. Bureau of Labor Statistics, the number of personal training jobs in the United States is slated to grow about 10 percent per year with over 330,000 personal training jobs forecasted by 2026. Many of these trainers work in health clubs, fitness or recreation centers, gyms, country clubs, hospitals, group fitness studios, resorts and at clients’ homes, making ideal points of contact with the end user.”
PainShield is an ultrasound device, consisting of a reusable driver unit and a disposable patch, which contains a proprietary therapeutic transducer. PainShield delivers a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area, while keeping the level of ultrasound energy at a safe and consistent level. Its range of applications includes acute and chronic pain resolution through its many mechanisms of action. The product has been acknowledged by several sports icons and has broad applications for sports injuries. PainShield can be used by patients at home or work or in a clinical setting and can be used even while the patient is sleeping. Patient benefits include ease of application and use, faster recovery time, high compliance, and increased safety and efficacy over existing devices that rely on higher-frequency ultrasound.
NanoVibronix Inc. (NASDAQ:NAOV) is a medical device company headquartered in Elmsford, NY with research and development in Nesher, Israel, that is focused on developing medical devices utilizing its proprietary and patented low intensity surface acoustic wave technology. The company’s technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including the disruption of biofilms and bacteria colonization, as well as providing pain relief. The devices can be administered at home without the assistance of medical professionals. The company’s primary products include PainShield®, UroShield™ and WoundShield™. Additional information about the company is available at: www.nanovibronix.com.
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Source: NanoVibronix, Inc.
Released May 9, 2018